Search

Your search keyword '"PSOTKA, MITCHELL"' showing total 507 results
Start Over Author "PSOTKA, MITCHELL"
507 results on '"PSOTKA, MITCHELL"'

51. Abstract 15759: Utility of the Sofa Score to Risk Stratify Patients in the Cardiac Intensive Care Unit at a Tertiary Care Center

Author

Raja, Anika I, Genovese, Leonard, Vyas, Ankit, BAGCHI, PRAMITA, Shah, Palak, Psotka, Mitchell, Bagnola, Aaron J, Flanagan, M C, Welch, Timothy, Rosner, Carolyn, Tehrani, Behnam N, Truesdell, Alexander, Damluji, Abdulla, Cole, Robert, Cooper, Lauren, Desai, Shashank, Moukhachen, Hala, Garofalo, Stephanie, Batchelor, Wayne, DEFILIPPI, Christopher, and Sinha, Shashank S

Published
2020
Full Text
View/download PDF

54. The Win Ratio Method in Heart Failure Trials: Lessons Learnt From Empulse

Author

Pocock, Stuart J., primary, Ferreira, João Pedro, additional, Collier, Timothy J., additional, Angermann, Christiane E., additional, Biegus, Jan, additional, Collins, Sean P., additional, Kosiborod, Mikhail, additional, Nassif, Michael E., additional, Ponikowski, Piotr, additional, Psotka, Mitchell A., additional, Teerlink, John R., additional, Tromp, Jasper, additional, Gregson, John, additional, Blatchford, Jonathan P., additional, Zeller, Cordula, additional, and Voors, Adriaan A., additional

Published
2023
Full Text
View/download PDF

55. Advanced Practice Provider Urgent Outpatient Clinic for Patients With Decompensated Heart Failure

Author

ROSNER, CAROLYN M., primary, LEE, SEIYON BEN, additional, BADRISH, NAROTHAM, additional, MAINI, ANEEL S., additional, YOUNG, KARL D., additional, VORGANG, CASSANDRA M., additional, BAGNOLA, AARON, additional, DESAI, SHASHANK S., additional, HAHNDORF, CAROLYN, additional, LOOBY, MARY, additional, PSOTKA, MITCHELL A., additional, O'CONNOR, CHRISTOPHER M., additional, and COOPER, LAUREN B., additional

Published
2023
Full Text
View/download PDF

56. AN UNCOMMON CAUSE OF HEART FAILURE: ACROMEGALIC CARDIOMYOPATHY CULMINATING IN ORTHOTOPIC HEART TRANSPLANTATION

Author

Dewanjee, Aditya, primary, Rayes, Danny, additional, Eltelbany, Moemen, additional, Kennedy, Jamie, additional, Raja, Anika, additional, Tehrani, Behnam Nonahal, additional, Shah, Palak, additional, Desai, Shashank, additional, Howard, Edward William, additional, Tang, Daniel Giunway, additional, Singh, Ramesh, additional, King, Christopher, additional, Moukhachen, Hala, additional, Psotka, Mitchell, additional, Young, Karl D., additional, Sinha, Shashank S., additional, and Gattani, Raghav, additional

Published
2023
Full Text
View/download PDF

57. UTILIZATION OF GUIDELINE DIRECTED MEDICAL THERAPY FOR HEART FAILURE IN CARDIOGENIC SHOCK SURVIVORS: AN INOVA SHOCK REGISTRY ANALYSIS

Author

Dimond, Matthew, primary, Shakoor, Unique, additional, Rosner, Carolyn Marie, additional, Psotka, Mitchell, additional, Lee, Seiyon, additional, Batchelor, Wayne B., additional, Damluji, Abdulla, additional, Desai, Shashank S., additional, Epps, Kelly C., additional, Flanagan, Michael C., additional, Moukhachen, Hala, additional, Raja, Anika, additional, Samadani, Taraneh, additional, Sherwood, Matthew William, additional, Singh, Ramesh, additional, Shah, Palak, additional, Tang, Daniel Giunway, additional, Tehrani, Behnam Nonahal, additional, Truesdell, Alexander George, additional, Young, Karl D., additional, Sinha, Shashank S., additional, and O'Connor, Christopher M., additional

Published
2023
Full Text
View/download PDF

61. Heart Failure Without a Reduced Ejection Fraction.

Author

Kumar, Sant and Psotka, Mitchell A.

Subjects
*HEART failure treatment, *SPIRONOLACTONE, *CARDIAC amyloidosis, *VENTRICULAR ejection fraction, *EMPAGLIFLOZIN, *HETEROCYCLIC compounds, *MEDICAL care costs, *DAPAGLIFLOZIN, *VALSARTAN, *SODIUM-glucose cotransporter 2 inhibitors, *HEART failure, *DISEASE management
Abstract

Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and death. HF is a clinical syndrome with diverse symptomatic presentations. Physicians generally divide patients with HF into 2 groups: those with a left ventricular ejection fraction (LVEF) greater than or equal to 50% and those with an LVEF less than 49%. This review focuses on the group of patients whose LVEF is greater than or equal to 50%. This classification of HF is referred to as HF with a preserved ejection fraction (HFpEF). Few beneficial therapies have been identified for this condition, possibly because of its heterogenous etiologies (eg, myocardial, vascular, metabolic, and other physiologic derangements). Clinicians should focus on diagnosing, treating, and preventing the etiologies that are known to cause HFpEF. Results from a small proportion of randomized controlled trials have shown therapeutic benefit for small molecules, although limited, if any, demonstrated mortality benefit has been noted. More research and investment are needed to decrease the burden of HFpEF and to discover lifesaving treatments for this growing population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

63. Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial

Author

Voors, Adriaan, Damman, Kevin, Teerlink, John, Angermann, Christiane, Collins, Sean, Kosiborod, Mikhail, Biegus, Jan, Ferreira, João Pedro, Nassif, Michael, Psotka, Mitchell, Tromp, Jasper, Brueckmann, Martina, Blatchford, Jonathan, Salsali, Afshin, Ponikowski, Piotr, University Medical Center Groningen [Groningen] (UMCG), Veterans Affairs Medical Center, San Francisco, California, University Hospital of Würzburg, Vanderbilt University [Nashville], Saint Luke's Mid America Heart Institute, University of Missouri [Kansas City] (UMKC), University of Missouri System, The George Institute for Global Health [Sydney] (GIGH), The University of Sydney, University of New South Wales [Sydney] (UNSW), Wrocław Medical University, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Universidade do Porto = University of Porto, Inova Heart and Vascular Institute [Falls Church, VA, USA] (IHVI), National University of Singapore (NUS), National University Health System [Singapore] (NUHS), Boehringer Ingelheim International GmbH, Medizinische Fakultät Mannheim, Elderbrook Solutions GmbH on behalf of Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Rutgers, The State University of New Jersey [New Brunswick] (RU), Rutgers University System (Rutgers), The trial was funded by the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance., BOZEC, Erwan, and Cardiovascular Centre (CVC)

Subjects
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Chronic kidney disease, Acute heart failure, SGLT2 inhibitor, Cardiology and Cardiovascular Medicine, Renal function, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Abstract

International audience; Aim: The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved clinical outcomes in patients hospitalized for acute heart failure. In patients with chronic heart failure, SGLT2 inhibitors cause an early decline in estimated glomerular filtration rate (eGFR) followed by a slower eGFR decline over time than placebo. However, the effects of SGLT2 inhibitors on renal function during a hospital admission for acute heart failure remain largely unknown.Methods and results: Between 1 and 5 days after a hospitalization for acute heart failure, 530 patients with an eGFR >20 ml/min/1.73 m2 were randomized to 10 mg of empagliflozin or placebo and treated for 90 days. Renal function and electrolytes were measured at baseline, and after 15, 30 and 90 days. We evaluated the effect of empagliflozin on eGFR over time and the impact of baseline eGFR on the primary hierarchical outcome of death, worsening heart failure events and quality of life. Mean baseline eGFR was 52.4 ml/min/1.73 m2 in the empagliflozin group and 55.7 ml/min/1.73 m2 in the placebo group. Empagliflozin caused an initial decline in eGFR (-2 ml/min/1.73 m2 at day 15 compared to placebo). At day 90, eGFR was similar between empagliflozin and placebo. Investigator-reported acute renal failure occurred in 7.7% of empagliflozin versus 12.1% of placebo patients. The overall clinical benefit (hierarchical composite of all-cause death, heart failure events and quality of life) of empagliflozin was unaffected by baseline eGFR.Conclusion: In patients hospitalized for acute heart failure, empagliflozin caused an early modest decline in renal function which was no longer evident after 90 days. Acute renal events were similar in both groups. The clinical benefit of empagliflozin was consistent regardless of baseline renal function.

Published
2022

64. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

Author

Biegus, Jan, primary, Voors, Adriaan A, additional, Collins, Sean P, additional, Kosiborod, Mikhail N, additional, Teerlink, John R, additional, Angermann, Christiane E, additional, Tromp, Jasper, additional, Ferreira, Joao Pedro, additional, Nassif, Michael E, additional, Psotka, Mitchell A, additional, Brueckmann, Martina, additional, Salsali, Afshin, additional, Blatchford, Jonathan P, additional, and Ponikowski, Piotr, additional

Published
2022
Full Text
View/download PDF

65. Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension

Author

Nathan, Steven D., primary, Fernandes, Peter, additional, Psotka, Mitchell, additional, Vitulo, Patrizio, additional, Piccari, Lucilla, additional, Antoniou, Katerina, additional, Nikkho, Sylvia M., additional, and Stockbridge, Norman, additional

Published
2022
Full Text
View/download PDF

66. Wearables in Cardiovascular Disease

Author

Kumar, Sanchit, primary, Victoria-Castro, Angela M., additional, Melchinger, Hannah, additional, O’Connor, Kyle D., additional, Psotka, Mitchell, additional, Desai, Nihar R., additional, Ahmad, Tariq, additional, and Wilson, F. Perry, additional

Published
2022
Full Text
View/download PDF

67. Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results from The Empulse Trial

Author

Voors, Adriaan, primary, Angermann, Christiane, additional, Teerlink, John, additional, Collins, Sean, additional, Kosiborod, Mikhail, additional, Biegus, Jan, additional, Ferreira, Joao Pedro, additional, Nassif, Michael, additional, Psotka, Mitchell, additional, Tromp, Jasper, additional, Bruekmann, Martina, additional, Blatchford, Jon, additional, Salasali, Afshin, additional, and Poniikowski, Piotr, additional

Published
2022
Full Text
View/download PDF

71. Cardiogenic Shock from Heart Failure versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and One-Year Outcomes

Author

Sinha, Shashank S., Rosner, Carolyn M., Tehrani, Behnam N., Maini, Aneel, Truesdell, Alexander G., Lee PhD, Seiyon Ben, Bagchi, Pramita, Cameron, James, Damluji, Abdulla A., Desai, Mehul, Desai, Shashank S., Epps, Kelly C., deFilippi, Christopher, Flanagan, M. Casey, Genovese, Leonard, Moukhachen, Hala, Park, James J., Psotka, Mitchell A., Raja, Anika, Shah, Palak, Sherwood, Matthew W., Singh, Ramesh, Tang, Daniel, Karl D., Young, Welch, Timothy, O’Connor, Christopher M., and Batchelor, Wayne B.

Subjects
Heart Failure, Male, Myocardial Infarction, Shock, Cardiogenic, Aftercare, Humans, Female, Hospital Mortality, Middle Aged, Article, Hospitals, Patient Discharge, Aged
Abstract

BACKGROUND: Little is known about clinical characteristics, hospital course, and longitudinal outcomes of patients with cardiogenic shock (CS) from heart failure (HF-CS) as compared to acute myocardial infarction (AMI-CS). METHODS: We examined in-hospital and one-year outcomes of 520 (219 AMI-CS, 301 HF-CS) consecutive patients with CS (1/3/2017–12/31/2019) in a single center registry. RESULTS: Mean age was 61.5±13.5 years, 71% were male, 22% were Black, and 63% had chronic kidney disease. The HF-CS cohort was younger (58.5 vs. 65.6 years, p

Published
2022

72. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial

Author

Kosiborod, Mikhail N., primary, Angermann, Christiane E., additional, Collins, Sean P., additional, Teerlink, John R., additional, Ponikowski, Piotr, additional, Biegus, Jan, additional, Comin-Colet, Josep, additional, Ferreira, João Pedro, additional, Mentz, Robert J., additional, Nassif, Michael E., additional, Psotka, Mitchell A., additional, Tromp, Jasper, additional, Brueckmann, Martina, additional, Blatchford, Jonathan P., additional, Salsali, Afshin, additional, and Voors, Adriaan A., additional

Published
2022
Full Text
View/download PDF

73. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative—Group 3 pulmonary hypertension

Author

Nikkho, Sylvia M., primary, Richter, Manuel J., additional, Shen, Eric, additional, Abman, Steven H., additional, Antoniou, Katerina, additional, Chung, Jonathan, additional, Fernandes, Peter, additional, Hassoun, Paul, additional, Lazarus, Howard M., additional, Olschewski, Horst, additional, Piccari, Lucilla, additional, Psotka, Mitchell, additional, Saggar, Rajan, additional, Shlobin, Oksana A., additional, Stockbridge, Norman, additional, Vitulo, Patrizio, additional, Vizza, Carmine Dario, additional, Wort, Stephen J., additional, and Nathan, Steven D., additional

Published
2022
Full Text
View/download PDF

74. Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes

Author

Sinha, Shashank S., primary, Rosner, Carolyn M., additional, Tehrani, Behnam N., additional, Maini, Aneel, additional, Truesdell, Alexander G., additional, Lee, Seiyon Ben, additional, Bagchi, Pramita, additional, Cameron, James, additional, Damluji, Abdulla A., additional, Desai, Mehul, additional, Desai, Shashank S., additional, Epps, Kelly C., additional, deFilippi, Christopher, additional, Flanagan, M. Casey, additional, Genovese, Leonard, additional, Moukhachen, Hala, additional, Park, James J., additional, Psotka, Mitchell A., additional, Raja, Anika, additional, Shah, Palak, additional, Sherwood, Matthew W., additional, Singh, Ramesh, additional, Tang, Daniel, additional, Young, Karl D., additional, Welch, Timothy, additional, O’Connor, Christopher M., additional, and Batchelor, Wayne B., additional

Published
2022
Full Text
View/download PDF

75. Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials

Author

DeFilippis, Ersilia M., primary, Echols, Melvin, additional, Adamson, Philip B., additional, Batchelor, Wayne B., additional, Cooper, Lauren B., additional, Cooper, Lawton S., additional, Desvigne-Nickens, Patrice, additional, George, Richard T., additional, Ibrahim, Nasrien E., additional, Jessup, Mariell, additional, Kitzman, Dalane W., additional, Leifer, Eric S., additional, Mendoza, Martin, additional, Piña, Ileana L., additional, Psotka, Mitchell, additional, Senatore, Fortunato Fred, additional, Stein, Kenneth M., additional, Teerlink, John R., additional, Yancy, Clyde W., additional, Lindenfeld, JoAnn, additional, Fiuzat, Mona, additional, O’Connor, Christopher M., additional, Vardeny, Orly, additional, and Vaduganathan, Muthiah, additional

Published
2022
Full Text
View/download PDF

77. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure:a multinational randomized trial

Author

Voors, Adriaan A., Angermann, Christiane E., Teerlink, John R., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, Joao Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Borleffs, C. Jan Willem, Ma, Changsheng, Comin-Colet, Joseph, Fu, Michael, Janssens, Stefan P., Kiss, Robert G., Mentz, Robert J., Sakata, Yasushi, Schirmer, Henrik, Schou, Morten, Schulze, P. Christian, Spinarova, Lenka, Volterrani, Maurizio, Wranicz, Jerzy K., Zeymer, Uwe, Zieroth, Shelley, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, Ponikowski, Piotr, Voors, Adriaan A., Angermann, Christiane E., Teerlink, John R., Collins, Sean P., Kosiborod, Mikhail, Biegus, Jan, Ferreira, Joao Pedro, Nassif, Michael E., Psotka, Mitchell A., Tromp, Jasper, Borleffs, C. Jan Willem, Ma, Changsheng, Comin-Colet, Joseph, Fu, Michael, Janssens, Stefan P., Kiss, Robert G., Mentz, Robert J., Sakata, Yasushi, Schirmer, Henrik, Schou, Morten, Schulze, P. Christian, Spinarova, Lenka, Volterrani, Maurizio, Wranicz, Jerzy K., Zeymer, Uwe, Zieroth, Shelley, Brueckmann, Martina, Blatchford, Jonathan P., Salsali, Afshin, and Ponikowski, Piotr

Abstract

The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failure is unknown. In this double-blind trial (EMPULSE; NCT04157751), 530 patients with a primary diagnosis of acute de novo or decompensated chronic heart failure regardless of left ventricular ejection fraction were randomly assigned to receive empagliflozin 10 mg once daily or placebo. Patients were randomized in-hospital when clinically stable (median time from hospital admission to randomization, 3 days) and were treated for up to 90 days. The primary outcome of the trial was clinical benefit, defined as a hierarchical composite of death from any cause, number of heart failure events and time to first heart failure event, or a 5 point or greater difference in change from baseline in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score at 90 days, as assessed using a win ratio. More patients treated with empagliflozin had clinical benefit compared with placebo (stratified win ratio, 1.36; 95% confidence interval, 1.09-1.68; P =0.0054), meeting the primary endpoint. Clinical benefit was observed for both acute de novo and decompensated chronic heart failure and was observed regardless of ejection fraction or the presence or absence of diabetes. Empagliflozin was well tolerated; serious adverse events were reported in 32.3% and 43.6% of the empagliflozin- and placebo-treated patients, respectively. These findings indicate that initiation of empagliflozin in patients hospitalized for acute heart failure is well tolerated and results in significant clinical benefit in the 90 days after starting treatment.

Published
2022

80. Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension

Author

Thomeas-McEwing, Vasiliki, primary, Psotka, Mitchell A., additional, Gamazon, Eric R., additional, Friedman, Paula, additional, Konkashbaev, Anuar, additional, Kubo, Michiaki, additional, Nakamura, Yusuke, additional, Ratain, Mark J., additional, Benza, Raymond L., additional, Cox, Nancy J., additional, Gomberg-Maitland, Mardi I., additional, and Maitland, Michael L., additional

Published
2022
Full Text
View/download PDF

81. Predicting Cardiac Structural And Functional Improvement On Left Ventricular Assist Device Support: The Externally Validated UCAR Score

Author

Kyriakopoulos, Christos P., primary, Taleb, Iosif, additional, Wever-Pinzon, Omar, additional, Selzman, Craig, additional, Kfoury, Abdallah, additional, Catino, Anna, additional, Tseliou, Eleni, additional, Stehlik, Josef, additional, Alharethi, Rami, additional, Fang, James C., additional, Koliopoulou, Antigone, additional, Goodwin, Matthew, additional, Kagawa, Hiroshi, additional, Dranow, Elizabeth, additional, Singh, Ramesh, additional, Psotka, Mitchell, additional, Birks, Emma, additional, Slaughter, Mark S., additional, Koenig, Steven, additional, Kyvernitakis, Andreas, additional, Hoffman, Karlee, additional, Guglin, Maya, additional, Kotter, John, additional, Vidic, Andrija, additional, Raval, Nirav, additional, Kanwar, Manreet, additional, Shah, Palak, additional, and Drakos, Stavros G., additional

Published
2022
Full Text
View/download PDF

84. FUNCTIONAL AND SYMPTOMATIC CLINICAL ENDPOINTS IN HEART FAILURE RESEARCH: INSIGHTS FROM THE HEART FAILURE COLLABORATORY (HFC) - ACADEMIC RESEARCH CONSORTIUM (ARC) SCIENTIFIC EXPERT PANEL

Author

Dimond, Matthew, primary, Fiuzat, Mona, additional, Psotka, Mitchell A., additional, O’Connor, Christopher M., additional, Consortium, Heart Failure Collaboratory-Academic Research, additional, Abraham, William T., additional, Ahmad, Tariq, additional, Anker, Stefan D., additional, Felker, Michael G., additional, Filippatos, Gerasimos, additional, Kitzman, Dalane W., additional, Leifer, Eric, additional, Lewis, Eldrin F., additional, Lindenfeld, JoAnn, additional, Mentz, Robert John, additional, Nkulikiyinka, Richard, additional, Schaber, Dan, additional, Sharma, Abhinav, additional, Solomon, Scott D., additional, Stockbridge, Norman, additional, Teerlink, John R., additional, Whellan, David J., additional, and Wittes, Janet T., additional

Published
2022
Full Text
View/download PDF

85. EMPAGLIFLOZIN IN PATIENTS HOSPITALIZED FOR DE NOVO VERSUS DECOMPENSATED CHRONIC HEART FAILURE: INSIGHTS FROM THE EMPULSE TRIAL

Author

Angermann, Christiane E., primary, Voors, Adriaan, additional, Collins, Sean P., additional, Kosiborod, Mikhail, additional, Biegus, Jan, additional, Ferreira, Joao Pedro, additional, Nassif, Michael, additional, Psotka, Mitchell, additional, Tromp, Jasper, additional, Blatchford, Jonathan, additional, Salsali, Afshin, additional, Kraus, Bettina, additional, Ponikowski, Piotr, additional, and Teerlink, John R., additional

Published
2022
Full Text
View/download PDF

91. LVAD decommissioning for myocardial recovery: Long-term ventricular remodeling and adverse events

Author

Gerhard, Eleanor F., primary, Wang, Lu, additional, Singh, Ramesh, additional, Schueler, Stephan, additional, Genovese, Leonard D., additional, Woods, Andrew, additional, Tang, Daniel, additional, Smith, Nicola Robinson, additional, Psotka, Mitchell A., additional, Tovey, Sian, additional, Desai, Shashank S., additional, Jakovljevic, Djordje G., additional, MacGowan, Guy A., additional, and Shah, Palak, additional

Published
2021
Full Text
View/download PDF

93. Abstract 12124: A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study

Author

Johansen, Niklas, primary, Vaduganathan, Muthiah, additional, Zahir, Deewa, additional, Fiuzat, Mona, additional, Defilippis, Ersilia M, additional, Januzzi, James L, additional, Butler, Javed, additional, O'Connor, Christopher, additional, Abraham, William T, additional, Psotka, Mitchell, additional, McMurray, John J, additional, Jensen, Jens-Ulrik Staehr, additional, Schou, Morten, additional, Torp-Pedersen, Christian, additional, Kober, Lars, additional, Gislason, Gunnar H, additional, and Biering-Sørensen, Tor, additional

Published
2021
Full Text
View/download PDF

94. Abstract 13324: One-Year Outcomes in Patients With Cardiogenic Shock: Insights From the Inova-Shock Registry

Author

Sinha, Shashank, primary, Rosner, Carolyn, additional, Tehrani, Behnam N, additional, Maini, Aneel, additional, Truesdell, Alexander G, additional, BAGCHI, PRAMITA, additional, Cameron, James, additional, Damluji, Abdulla, additional, desai, mehul, additional, Desai, Shashank, additional, Epps, Kelly C, additional, Defilippi, Christopher, additional, Genovese, Leonard, additional, Moukhachen, Hala, additional, Park, James, additional, Psotka, Mitchell, additional, Raja, Anika, additional, Sherwood, Matthew W, additional, Singh, Ramesh, additional, Tang, Daniel, additional, Young, Karl, additional, O'Connor, Christopher M, additional, and Batchelor, Wayne B, additional

Published
2021
Full Text
View/download PDF

95. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.

Author

Biegus, Jan, Voors, Adriaan A, Collins, Sean P, Kosiborod, Mikhail N, Teerlink, John R, Angermann, Christiane E, Tromp, Jasper, Ferreira, Joao Pedro, Nassif, Michael E, Psotka, Mitchell A, Brueckmann, Martina, Salsali, Afshin, Blatchford, Jonathan P, and Ponikowski, Piotr

Subjects
HEART failure, BRAIN natriuretic factor, SODIUM-glucose cotransporter 2 inhibitors, EMPAGLIFLOZIN, HEART failure patients
Abstract

Aims Effective and safe decongestion remains a major goal for optimal management of patients with acute heart failure (AHF). The effects of the sodium–glucose cotransporter 2 inhibitor empagliflozin on decongestion-related endpoints in the EMPULSE trial (NCT0415775) were evaluated. Methods and results A total of 530 patients hospitalized for AHF were randomized 1:1 to either empagliflozin 10 mg once daily or placebo for 90 days. The outcomes investigated were: weight loss (WL), WL adjusted for mean daily loop diuretic dose (WL-adjusted), area under the curve of change from baseline in N-terminal pro-B-type natriuretic peptide levels, hemoconcentration, and clinical congestion score after 15, 30, and 90 days of treatment. Compared with placebo, patients treated with empagliflozin demonstrated significantly greater reductions in all studied markers of decongestion at all time-points, adjusted mean differences (95% confidence interval) at Days 15, 30, and 90 were: for WL −1.97 (−2.86, −1.08), −1.74 (−2.73, −0.74); −1.53 (−2.75, −0.31) kg; for WL-adjusted: −2.31 (−3.77, −0.85), −2.79 (−5.03, −0.54), −3.18 (−6.08, −0.28) kg/40 mg furosemide i.v. or equivalent; respectively (all P < 0.05). Greater WL at Day 15 (i.e. above the median WL in the entire population) was associated with significantly higher probability for clinical benefit at Day 90 (hierarchical composite of all-cause death, heart failure events, and a 5-point or greater difference in Kansas City Cardiomyopathy Questionnaire total symptom score change from baseline to 90 days) with the win ratio of 1.75 (95% confidence interval 1.37, 2.23; P < 0.0001). Conclusion Initiation of empagliflozin in patients hospitalized for AHF resulted in an early, effective and sustained decongestion which was associated with clinical benefit at Day 90. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

97. Fulminant cardiogenic shock due to cardiac sarcoidosis

Author

Genovese, Leonard, primary, Dey, Amit K., additional, Cole, Robert T., additional, Cooper, Lauren B., additional, Desai, Shashank, additional, May, Christopher W., additional, Sarin, Eric, additional, Shah, Palak, additional, Sinha, Shashank S., additional, and Psotka, Mitchell A., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results